Satellos Bioscience Inc. (MSCL : TSX)
Common Stock
$12.71
CAD
-0.14 (-1.09%)
Last updated: 2026-07-14
MSCL
Satellos Bioscience Inc.
WealthAwesomePerformance
1 Day
-1.09%
1 Week
+10.04%
1 Month
+58.48%
YTD
+51.31%
Key Statistics
Market Cap
$267.68M
52W High
$18.98
52W Low
$6.36
P/E Ratio
-
50 Day MA
$9.72
200 Day MA
$10.37
Beta
1.17
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/14/2026 | $12.86 | $12.86 | $12.46 | $12.71 | $12.71 | 4,112 |
| 7/13/2026 | $13.74 | $13.74 | $12.20 | $12.85 | $12.85 | 38,461 |
| 7/10/2026 | $13.56 | $14.15 | $13.35 | $13.53 | $13.53 | 26,751 |
| 7/9/2026 | $12.69 | $13.75 | $12.22 | $13.28 | $13.28 | 91,570 |
| 7/8/2026 | $12.25 | $13.65 | $12.25 | $12.62 | $12.62 | 219,239 |
| 7/7/2026 | $11.58 | $11.95 | $10.86 | $11.55 | $11.55 | 11,729 |
| 7/6/2026 | $10.95 | $12.08 | $10.87 | $11.56 | $11.56 | 13,838 |
| 7/3/2026 | $10.17 | $10.91 | $10.17 | $10.91 | $10.91 | 2,030 |
| 7/2/2026 | $10.67 | $10.91 | $10.20 | $10.20 | $10.20 | 2,233 |
| 6/30/2026 | $11.25 | $11.25 | $10.63 | $10.66 | $10.66 | 129,700 |
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 39.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+39.0% Upside
Current Price
C$12.71
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
94.6%
Annualized
90-Day Vol
95.9%
Annualized
Trend (90d)
+27.3%
Annualized drift
90d Mean
C$14.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$13.13 | C$9.47 – C$18.20 |
| 60 trading days | C$13.56 | C$8.55 – C$21.52 |
| 90 trading days | C$14.01 | C$7.96 – C$24.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-30.02M
- Profit Margin
- 0.00%
- ROE (TTM)
- -50.74%
- EPS (Diluted)
- -2.54
- Book Value
- 4.81
🔄 Recent Splits
1-for-12
Jan 30, 2026
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About MSCL
Articles Featuring MSCL.TO
Latest articles and analysis covering MSCL.TO
Why Satellos Bioscience Inc. stock is plummeting today
Satellos Bioscience Inc. experienced a notable decline in its stock price today, raising questions about the company's future amid a lack of recent positive developments.
Why Satellos Bioscience Inc. stock is skyrocketing today
Satellos Bioscience Inc. stock surged 5.23% today, driven by positive developments in its clinical trials for Duchenne muscular dystrophy. This momentum reflects growing investor confidence in the company's future prospects.
Why Satellos Bioscience Inc. stock is skyrocketing today
Satellos Bioscience Inc. saw its stock price soar by over 9% today, driven by positive investor sentiment regarding its clinical advancements and regulatory approvals.
Why Satellos Bioscience Inc. stock is skyrocketing today
Satellos Bioscience Inc. has experienced a notable stock price increase of 12.90%, attributed to its recent FDA Fast Track designation for SAT-3247, which could expedite its development for Duchenne muscular dystrophy.
Why Satellos Bioscience Inc. stock is sliding today
Satellos Bioscience Inc. experienced a 4.84% drop in its stock price, closing at CA$11.00, raising concerns about its market position and future prospects.
Why Satellos Bioscience Inc. stock is skyrocketing today
Satellos Bioscience Inc. (MSCL.TO) has seen a notable increase in its stock price, fueled by recent regulatory approvals and strategic corporate initiatives. Investors are optimistic about the company's future in treating Duchenne muscular dystrophy.
Why Satellos Bioscience Inc. stock is rising today
Satellos Bioscience Inc. has seen a 3.24% rise in its stock price, driven by recent advancements in its clinical programs and the potential for a Nasdaq listing.
Why Satellos Bioscience Inc. stock is plummeting today
Satellos Bioscience Inc. (MSCL.TO) experienced a significant drop of 5.24% in its stock price during the last trading session, closing at CA$10.66. This decline raises questions about investor confidence amid a lack of recent positive news.
Why Satellos Bioscience Inc. stock is skyrocketing today
Satellos Bioscience Inc. has surged by over 10% in one trading day, driven by investor optimism surrounding its clinical programs and strategic initiatives.
Why Satellos Bioscience Inc. stock is skyrocketing today
Satellos Bioscience Inc. has seen its stock price soar by over 10% in a single trading day, reflecting investor optimism regarding its clinical advancements in treating Duchenne muscular dystrophy.
Why Satellos Bioscience Inc. stock is skyrocketing today
Satellos Bioscience Inc. has experienced a remarkable 21.31% increase in its stock price today, driven by optimism surrounding its clinical developments. Investors are keenly watching this biotech firm as it aims to make significant strides in treating Duchenne muscular dystrophy.
Why Satellos Bioscience Inc. stock is skyrocketing today
Satellos Bioscience Inc. has seen its stock price soar by 7.19% in the latest trading session, closing at CA$8.50. This surge reflects growing investor confidence amid ongoing developments in its clinical trials.
Why Satellos Bioscience Inc. stock is tanking today
Satellos Bioscience Inc. (MSCL.TO) closed down 1.60% in the last trading session, raising questions about its market stability amid no recent news to support its valuation.
Why Satellos Bioscience Inc. stock is rising today
Satellos Bioscience Inc. has seen a 2.66% increase in its stock price today, closing at CA$8.10. This rise is attributed to investor optimism surrounding the company's ongoing clinical trials and strategic initiatives.
Why Satellos Bioscience Inc. stock is sliding today
Satellos Bioscience Inc. experienced a 2.50% decline in its stock price today, closing at CA$8.18. This drop raises questions about the company's market position and future performance as it navigates key clinical trials and strategic financial decisions.
Why Satellos Bioscience Inc. stock is gaining today
Satellos Bioscience Inc. has gained 1.65% today, closing at CA$8.65, as it continues to make strides in its clinical trials for Duchenne muscular dystrophy.
Why Satellos Bioscience Inc. stock is rising today
Satellos Bioscience Inc. shares rose by 3.54%, reflecting optimism surrounding its clinical programs. Investors are keenly watching the progress of SAT-3247, which targets Duchenne muscular dystrophy.
